Director at $SCI sells 2,514 shares in insider sale

Ellen Ochoa, a director at the company $SCI, recently engaged in insider trading by selling 2,514 shares of the company on August 26, 2025, for an estimated sum of $199,636. This sale accounted for approximately 100.0% of her shares of this particular class of stock, leaving her with zero shares of $SCI stock in this category.

In the past six months, $SCI insiders have been actively involved in trading $SCI stock on the open market, with a total of 15 transactions recorded. Notably, all 15 transactions were sales, with no purchases made by insiders during this period. Among the significant figures involved in these transactions are THOMAS L. RYAN, the CEO & Chairman, who made five sales totaling 235,609 shares amounting to an estimated $19,216,192, SUMNER J III WARING, the President, who conducted two sales of 56,100 shares worth $4,295,392, JOHN H FAULK, the SVP and COO, who sold 29,100 shares valued at $2,355,706, and TONY COELHO, who completed four sales of 19,750 shares totaling $1,558,182. Ellen Ochoa’s recent sale of 2,514 shares for $199,636 is also part of this insider trading activity.

Meanwhile, in terms of hedge fund activity related to $SCI stock, there have been notable shifts in recent times. Among the moves made by institutional investors, T. ROWE PRICE INVESTMENT MANAGEMENT, INC. reduced their portfolio by 2,969,370 shares (equivalent to a 93.8% decrease) in the second quarter of 2025, with an estimated value of $241,706,718. On the other hand, AQR CAPITAL MANAGEMENT LLC added 1,033,374 shares (representing a 386.5% increase) to their portfolio during the same period, amounting to approximately $84,116,643.

Moreover, members of Congress have been involved in trading $SCI stock, with a total of two transactions recorded in the past six months. Of these trades, one was a purchase and the other a sale. For instance, REPRESENTATIVE LISA C. MCCLAIN made two trades, one purchase valued at up to $15,000 on June 24 and one sale worth up to $15,000 on July 16.

In terms of analyst ratings for $SCI, two firms have issued buy ratings on the stock recently, with no sell ratings reported. Noteworthy reports include an “Outperform” rating by Oppenheimer on August 21, 2025, and a “Buy” rating by UBS on May 2, 2025. Additionally, various analysts have provided price targets for $SCI, with a median target of $90.0 based on insights from three analysts. Scott Schneeberger from Oppenheimer, John Ransom from Raymond James, and A.J. Rice from UBS have set target prices of $91.0, $90.0, and $88.0, respectively, on different dates in 2025.